“As it stands … we face the real prospect that the written explanation requirement of section 112 will be a more difficult criterion to meet than validation. Amgen and allow Juno so as not to be disturbed. “
The patent world is in training for the upcoming Supreme Court amgen vs sanofi case. This is the first time in his 75 years or more that the Supreme Court has evaluated the meaning and scope of the enablement requirement of 35 USC §112. Protecting groundbreaking and pioneering inventions is difficult.
But waiting is an equally important Section 112 case. . Therefore, the petitioner argued, “‘Written description of the invention’ [is] To be measured by a statutory standard “in complete, clear, concise, and precise terms so that a person skilled in the art can make and use the same”. Section 112 Validation Matters amgen vs sanofi.
a twist with Juno V. Kite The Supreme Court rejected Juno’s petition for certification in November and, interestingly, at the same conference that granted Amgen’s petition. Denial is usually the end of the road. But the court has a golden opportunity to correct that oversight by granting Juno’s motion for retrial, which was filed in November 2022 and is due to be considered on her January 6th this Friday. increase.
Rehearsal is necessary to avoid “doctrinal chaos”
Admittedly, successful appeals are extremely rare. Supreme Court rules actively discourage simply filing petitions for rehearing. Nonetheless, courts have occasionally granted them, including a significant patent case some 70 years ago. Graver Mfg. Co. vs. Linde Co.339 US 605 (1950).
Junod’s motion for retrial explains that if the court denies the Federal Circuit’s unwritten “full coverage” requirement: Amgen In that case, it would “deeply question the court’s ‘possess full scope’ test applied to assessing ‘written descriptions,’ which would challenge this case.” ” Rehr’g Pet. 1. Taking the characterization further, Amgen Recognizing the precedent of the Federal Circuit, Juno The decision to run for office would lead to doctrinal confusion for the jurisprudence of Article 112 to move forward.
As one of us explained elsewhere, Juno This decision imposes significant new burdens on inventors, well beyond those enacted by Congress under the Patent Act.Inference of Juno The inventor must demonstrate “ownership” of the “full scope of the claimed invention,” including both “known and unknown” embodiments. If this criterion is ultimately upheld, innovators such as Sloan Kettering will hopefully generate millions of antibody fragments (new therapeutics) when these resources can be better deployed in breakthrough cancers Years must be spent creating and testing the traditional prior art component of the law. research. therefore, Juno In a single ruling, we believe the Court of Appeals went too far and the Supreme Court should have granted a letter of appeal to correct the legal error.
However, the jurisprudence scenario becomes more worrisome once one understands the intertwining of enablement and written description requirements under current case law. In the past, written explanations were primarily limited to priority issues. Under both the Federal Circuit’s current approach and that of the US Patent and Trademark Office and the Patent Trial and Appeal Board, it is often impossible to distinguish between the “enablement” element and the “written description” element. Both the enablement analysis and the written description analysis often take into account, for example, the presence or absence of working examples of the claimed invention. Both analyzes frequently assess the unpredictability of the technique and the amount of experimentation required. For example see, Boston Scientific vs. Johnson & Johnson647 F.3d 1353 (Fed.Cir.2011); Novozymes A/S vs. DuPont Nutrition Biosciences APS723 F.3d 1336 (Fed. Cir. 2013).
Avoid Pyrrhus Victory
The concerns here are: Amgen but you can Juno If the Federal Circuit decides, it is likely that the revised validation criteria and enhanced written explanation requirements will remain. Pioneering patents may be invalidated under section 112.
The result would be an amazing historic change in law. As noted above, traditionally the written description requirement was seldom used to monitor the sufficiency of the specification for providing adequate guidance to the skilled craftsman. The written description requirement also ensured that the claim amendment was fully supported by the original specification. The enablement requirement, on the other hand, has taken the lead in ensuring that the details of the invention as set forth are sufficient for one skilled in the art to practice the claimed invention. That’s why the Federal Circuit adopted it. wand cause. (Of course, for the sake of argument, we acknowledge the Federal Circuit’s decision. Ariad Pharmaceuticals, Inc. v.Eli Lilly & Company598 F.3d 1336 (Fed. Cir. 2010) (en banc), validation and written description are two different requirements, but there is a healthy debate going on on that point).
As it stands, however, we are faced with the real prospect that the written explanation requirement of section 112 will be a more difficult standard to meet than enablement if the court overturns it in its next judgment. Amgen and allow Juno Stay undisturbed. Amgen will win the Supreme Court in a technical sense, but for the pioneering innovators and all those who advocate for each other, the statute, and congress for clearer intentions and more consistent innovation-promoting standards, it’s pure. would be a great victory.
Not All Lost: Hold or Grant Juno petition
Now back to the topic. All is not lost. By granting Juno’s request for a retrial, the Supreme Court has an opportunity to sidestep the legal quagmire. Assuming that the Supreme Court does not completely and unequivocally affirm, Amgengranting Juno’s petition for rehearing could be in the form of a GVR (grant, vacate, and remand), but the Federal Circuit has decided that the Supreme Court’s future validation guidance (and possibly section 112 wider) in AmgenAt the very least, the court decided that Juno’s request for a retrial should be Amgen is determined.
Judge Michelle consulted with Juno Therapeutics during the Federal Circuit proceedings, and Matthew Dowd drafted a brief for REGENXBio’s defense team in Juno’s case.
Image Source: Deposit Photo
Image ID: 9522064
Author: Iofoto
